PT  - JOURNAL ARTICLE
AU  - SONG PENG
AU  - WENHONG DONG
AU  - QIANGQIANG CHU
AU  - JIA MENG
AU  - HAITAO YANG
AU  - YINGYING DU
AU  - YU SUN
AU  - ROBERT M. HOFFMAN
TI  - Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer
AID  - 10.21873/invivo.12395
DP  - 2021 May 01
TA  - In Vivo
PG  - 1437--1441
VI  - 35
IP  - 3
4099  - http://iv.iiarjournals.org/content/35/3/1437.short
4100  - http://iv.iiarjournals.org/content/35/3/1437.full
SO  - In Vivo2021 May 01; 35
AB  - Background/Aim: Small-cell lung cancer (SCLC) is a recalcitrant disease with liver and other metastasis. The present study evaluated the efficacy of the traditional Chinese medicine Brucea javanica oil (BJO) combined with anlotinib, a multi-tyrosine kinase inhibitor with anti-angiogenic activity, on a nude-mouse model of SCLC liver metastasis. Materials and Methods: The mouse model was established by injecting NCI-H446 cells (1×106) in Matrigel (20 μl) into the upper liver lobe. All animals were randomized and assigned to three groups: Control (n=8); anlotinib alone (n=8; 3 mg/kg, qd×14+7-day interval with two cycles, oral); anlotinib plus BJO (n=8; 3 mg/kg anlotinib qd×14+7-day interval with two cycles, orally; BJO: 1 g/kg, qd×6 weeks, orally). Body weight was determined every week. Six weeks after initial treatment, tumors were collected for analysis of angiogenesis using immunohistochemistry. Results: The combination of anlotinib and BJO significantly inhibited growth of SCLC liver metastases and angiogenesis more than anlotinib monotherapy (p=0.043). In addition, BJO alleviated body-weight loss associated with anlotinib therapy, including general mouse condition. Conclusion: The results of the present study indicate that the combination of anlotinib with BJO is promisingly active against liver metastases of SCLC, and has clinical potential.